Shares of a company involved in exporting, marketing & distributing finished formulations of pharmaceutical drugs and API surged nearly 3 percent on Tuesday, after the company announced record date for bonus issue in 1:1 ratio.
With a market cap of Rs. 1,076 crores, at 02:51 p.m., the shares of Remus Pharmaceuticals Limited were trading in the green at Rs. 1,826 on NSE, up by around 1.5 percent, as compared to its previous closing price of Rs. 1,798.3.
What’s the News
As per the latest regulatory filings with the NSE, Remus Pharmaceuticals Limited has fixed Friday, 4th July 2025, as the ‘Record Date’ for the purpose of determining the eligibility of Shareholders entitled for issuance of Bonus Equity Shares in a 1:1 ratio.
This means that, the shareholders will receive 1 new fully paid-up equity shares for every 1 existing fully paid-up equity share of Rs. 10 each held by them on the aforesaid Record Date in accordance with the approval of the shareholders obtained through Postal Ballot on 23rd June 2025.
Financials & More
Remus Pharma reported a significant growth in revenue from operations, experiencing a rise of nearly 88 percent YoY, increasing from Rs. 185 crores in H2 FY24 to Rs. 348 crores in H2 FY25. Similarly, its net profit increased during the same period from Rs. 19 crores to Rs. 21 crores, representing a marginal growth of 10.5 percent YoY.
Remus Pharmaceuticals Limited is engaged in the business of marketing and distribution of API (Active Pharmaceutical Ingredient) and finished formulations of pharmaceutical drugs, along with the provision for technical consultancy services in various countries, including India.
The company has a growing portfolio of 620+ registered products, 640+ MOH submitted/under evaluation, 745+ dossiers prepared and for registration of products in major geographies, with an aim for 2000 new filings in the next 3 years.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
